Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 5/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.40 |
| ▸ | PGK1 | P00558 | 2/20 | 0.40 |
| ▸ | PGK2 | P07205 | 2/20 | 0.40 |
| ▸ | PTPRB | P23467 | 3/20 | 0.40 |
| ▸ | PTPRC | P08575 | 3/20 | 0.40 |
| ▸ | CDC25A | P30304 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8812398 | 0.83 | PTPN5 (0.40) | PTPN1PTPN2PTPN6PTPN11PGK1 | |
| SCHEMBL3736625 | 0.81 | PTPN1 (0.41) | PTPN1PTPN2PTPRC | |
| SCHEMBL3747190 | 0.81 | PTPN1 (0.39) | PTPN1PTPN2PTPRC | |
| SCHEMBL8812977 | 0.81 | PTPN5 (0.38) | PTPN1PTPN2PTPN6PTPN11PGK1 | |
| SCHEMBL4955857 | 0.80 | PTPN1 (0.40) | PTPN1PTPN5 | |
| SCHEMBL7598727 | 0.79 | PTPN1 (0.37) | PTPN1PTPN2PTPN6PTPN11PGK1 | |
| SCHEMBL642521 | 0.79 | ALDH1A1 (0.42) | PGK1PGK2PTPN5 | |
| SCHEMBL5166721 | 0.78 | PTPN1 (0.36) | PTPN1PTPN2PTPN6PTPN11PGK1 | |
| SCHEMBL7164043 | 0.77 | PTPN1 (0.44) | PTPN1PTPN2PTPN6PTPN11PGK1 | |
| SCHEMBL642868 | 0.76 | PGK1 (0.42) | PTPN1PGK1PGK2PTPN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765332-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006009876-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-1268494-A1 | SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS | Merck Frosst Canada & Co. (CA) | 2003-01-02 | — | — | EP | disclosed |
| US-6498151-B2 | PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-12-24 | — | — | US | disclosed |
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-07-11 | — | — | US | disclosed |
| WO-2001070753-A1 | SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | PTPA, PTPN1, PTPRS | PTPN1 2/4885PTPN2 12/4885PTPN6 14/4885 |
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | PTPRF, PTPRS, PTPRO | PTPN1 13/4885PTPN2 24/4885PTPN6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.